Physician profile
Joy J De Guzman
NPI 1891173431
$6,475.11
in general payments reported to CMS, 2019-2025
43 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,023 · 2022: $998 · 2023: $1,083 · 2024: $894 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,325 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,324.88 |
| Education | $129.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,153.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $581.57 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $528.18 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $452.43 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $420.71 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $403.46 | 2021-2025 | |
| Abbott Laboratories | $305.78 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $229.46 | 2021-2025 | Tepezza, Repatha, Otezla |
| Astellas Pharma US INC | $217.18 | 2021-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $204.63 | 2025 | Recorlev, Gvoke Hypopen |
| Sequel Med Tech, LLC | $189.21 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $178.51 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.45 | 2021-2024 | Jardiance |
| Corcept Therapeutics | $123.64 | 2024-2025 | Korlym |
| Radius Health, INC. | $119.09 | 2025 | Tymlos |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $108.76 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $105.85 | 2025 | |
| Madrigal Pharmaceuticals | $99.59 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $88.25 | 2021-2024 | Arexvy, Shingrix |
| Pfizer INC. | $78.62 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.27 | 2022 | |
| Tandem Diabetes Care, INC. | $68.46 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $52.06 | 2025 | Unithroid |
| Eisai INC. | $51.70 | 2021 | |
| Endo USA, INC. | $47.66 | 2025 | Aveed |
| Dexcom, INC. | $43.80 | 2021-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $41.23 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Soleno Therapeutics, INC. | $34.88 | 2025 | Vykat Xr |
| Exact Sciences Corporation | $30.41 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $29.94 | 2021-2022 | |
| Chiesi USA, INC. | $27.98 | 2025 | Mycapssa |
| Olympus America INC. | $27.75 | 2023 | Spiration Valve System |
| Ibsa Pharma INC. | $23.98 | 2024 | Flector, Tirosint, Licart |
| Globus Medical, INC. | $22.90 | 2025 | Senza |
| Amarin Pharma, INC. | $22.05 | 2022 | |
| Kyowa Kirin, INC. | $20.57 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.38 | 2022 | |
| Alvogen INC | $19.37 | 2025 | Teriparatide |
| Cequr Corporation | $18.57 | 2024 | Cequr Simplicity |
| Teva Pharmaceuticals USA, INC. | $17.04 | 2021 | |
| Seqirus USA INC | $15.57 | 2024 | Fluad, Flucelvax |
| Tolmar, INC. | $14.24 | 2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy De Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.